Who gets a second RSV antibody this season: AAP widened the list, CDC did not

Editorial context for parents, not medical advice.

The most important infant-health development this week is not another celebrity birth. It is a split between two official lists for the same product.

On 2 September 2026 the American Academy of Pediatrics published its 2026–27 RSV policy and technical report. Pediatric offices are still absorbing the change this week: more toddlers aged 8 through 19 months are now on AAP’s second-season list. CDC’s written recommendation for that age band is still narrower. Parents walking into a well-child visit this month can get two different answers depending on which document the clinic printed.

## Background

RSV remains the leading cause of infant hospitalization in the United States. Most healthy older toddlers recover at home. The babies who fill PICU beds are the youngest infants and a smaller group of children with lung, heart, neuromuscular, or immune risk.

Families now have three tools, not one:

- A maternal vaccine (Pfizer’s Abrysvo) given at 32–36 weeks of pregnancy during RSV season in most of the U.S.
- A long-acting monoclonal antibody for the infant: nirsevimab (Beyfortus) or clesrovimab (Enflonsia).
- For some children, a second-season dose as they enter their second winter.

AAP and CDC still agree on the first-season rule: every infant under 8 months born during or entering their first RSV season should be protected, unless the pregnant parent received Abrysvo at least 14 days before birth. Most healthy term babies need one path, not both.

The disagreement is the second winter.

## What changed

AAP expanded second-season eligibility for ages 8–19 months. The widened group includes children born before 32 weeks, children with significant congenital heart disease, certain chronic lung or neuromuscular conditions, and children with Down syndrome or similar chromosomal differences that raise RSV risk.

CDC’s current public language still tracks a tighter high-risk set: children who would have been on the old monthly palivizumab schedule, plus American Indian and Alaska Native children. Immunize.org’s expert page, last reviewed 23 September 2026, spells out that split so clinics do not pretend the two documents are identical.

That is the week’s operational story. Product is sitting in refrigerators. The eligibility spreadsheet is not one spreadsheet.

## Competing viewpoints

**AAP.** The old palivizumab box left high-risk toddlers unprotected because the monthly shot was expensive and narrowly indicated. Nirsevimab is one dose. The evidence now supports covering a broader second-season group.

**CDC-aligned text.** Keep the second-season dose for the highest-risk children. Expanding the list before payers and supply are aligned can create a recommendation that many offices cannot fill.

**Hospitals and insurers.** First-season doses already stall in the nursery because the antibody is not carved out of the birth bundle. A wider second-season list raises the same invoice fight in clinic.

**Parents.** One group wants every extra layer. Another group declined the maternal vaccine and is unsure about an antibody. A third group assumes last year’s “not eligible” still applies. The third group is the one this week’s AAP expansion is meant to catch.

## What to watch next

- Whether CDC publishes an aligned second-season list before peak season.
- Whether Medicaid and commercial plans pay for AAP’s wider group or only the CDC list.
- Local RSV onset. Southern states often start earlier.
- Nursery billing for first-season doses when the pregnant parent was not vaccinated in time.

Ask your pediatric office which document they are using this week — AAP or CDC — and write the answer down before you leave.

Sources: AAP 2026–27 RSV policy and technical report (2 September 2026); HealthyChildren.org; CDC infant RSV pages; Immunize.org Ask the Experts RSV page reviewed 23 September 2026.